Onesource Specialty Pharma Earns EU GMP Certification for Bangalore Facility

Onesource Specialty Pharma's Bangalore facility has achieved a significant milestone with its EU GMP Certificate of Compliance. The certificate, effective April 27, 2026, was issued by a German regulatory authority following an inspection on October 14, 2025. It confirms the facility's adherence to EU Good Manufacturing Practice (GMP) requirements for sterile products, including aseptic small volume liquids, secondary packing, and quality control testing.

Key Announcement

Onesource Specialty Pharma announced that its Sterile Product Division (SPD) in Bangalore has received an EU GMP Certificate of Compliance. This certification validates the facility's compliance with EU GMP standards.

Market Access Opens

Securing an EU GMP certificate is a critical step for pharmaceutical companies aiming to access the highly regulated European Union market. This approval signifies that the Bangalore facility's manufacturing processes and quality control systems meet stringent EU standards, opening significant opportunities to export sterile pharmaceuticals directly into EU member states.

Previous Accreditations

Onesource Specialty Pharma, formerly known as Lumina Datamatics Limited, has been growing its pharmaceutical operations. The company's Sterile Product Division already holds significant international accreditations, including approvals from the US-FDA, Health Canada, ANVISA (Brazil), and TGA (Australia). These prior approvals demonstrate a commitment to global quality standards, supporting this latest EU GMP approval.

Impact of Certification

• Market Access: Direct access to the EU market for sterile products made at the Bangalore facility.
• Revenue Potential: Enhanced export sales potential and revenue diversification.
• Credibility Boost: Strengthened global reputation and product quality validation.
• Competitive Edge: A stronger competitive position against firms lacking EU GMP certification for sterile products.
• Regulatory Alignment: Alignment with evolving international pharmaceutical regulations.

Potential Challenges

While this is a positive development, the company will need to navigate complex supply chains and strict regulatory oversight in the EU. Competition from established EU market players continues.

Industry Standing

The certification positions Onesource Specialty Pharma alongside Indian peers like Divi's Laboratories and Laurus Labs, who also have EU GMP-approved facilities for key products. These peers have used similar approvals to build a strong presence in regulated global markets.

Next Steps for Investors

• Timeline for starting sterile product exports to the EU.
• New European orders and sales pipeline.
• Plans for capacity expansion or new EU-targeted products.
• Revenue contribution from the Sterile Product Division.
• Management's outlook on the certification's strategic impact.